evaluation of Safety and efficacy of anti inflammatory regimens in COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; COVID-19; U07.1 COVI

• Registration Number: IRCT20200318046812N2
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 906

Inclusion Criteria

Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive RTPCR test for COVID-19
Requiring hospitalization
Patient's age between 16 and 100 years
Signed informed consent form

Exclusion Criteria

Past history of hospitalization or treatment in hospital for COVID-19 disease
Receiving other antiviral medications such as (Hydroxychloroquine, Kaletra, Ribavirin, Oseltamivir)
Uncontrolled diabetes
Astma
Chemotherapy in the past month
Taking immunosuppressive drugs
Chronic liver or renal failure
Taking daily systemic corticosteroids
HIV
GI bleeding
Pregnancy or Lactation
Uncontrolled bacterial infection

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Admission to intensive care unit. Timepoint: Once (when admitted to intensive care unit). Method of measurement: Hospital records.